News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Daxor Corporation (DXR) Announces Filing of Form N-CSR for June 30, 2012 and Volumex Kit Sales for the First Six Months of 2012


9/4/2012 9:24:28 AM

NEW YORK, NY--(Marketwire - September 04, 2012) -

Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations, filed a Form N-CSR today disclosing its schedule of portfolio holdings as of June 30, 2012. Copies of the form have been mailed to the Company's shareholders. The Company also disclosed its results for the six months ended June 30, 2012 in the Form N-CSR.

For the six months ended June 30, 2012, the Company's revenue from the sale of Volumex Kits increased by 3% from the same period in 2011. There were 66 Blood Volume Analyzers in service at June 30, 2012 versus 58 instruments at June 30, 2011. There is additional disclosure regarding the Company's Operating Division in the Form N-CSR which was filed today.

The Company recently received a refund of federal taxes of approximately $2,090,000. The loss for the year ended December 31, 2011 was used to offset taxes paid for the years ended December 31, 2010 and 2009 which generated the refund.

The Company used part of the proceeds from the tax refund to pay a dividend of $0.10 per share on August 24, 2012. Management elected to use the remainder of the proceeds to help fund its medical instrumentation and biotechnology operations.

Dr. Joseph Feldschuh, the President of Daxor, said: "We don't know if this improvement in the sale of Volumex Kits will continue. We realize there are no guarantees but remain hopeful that members of the medical community will understand the need for measuring patient's blood volume precisely rather than using surrogate tests and clinical guesstimates which can be grossly inaccurate. The precise knowledge of a patient's blood volume is essential for optimally treating critically ill and post operative patients."


Contact Information:
Daxor Corporation:
David Frankel
212-330-8504
Chief Financial Officer
dfrankel@daxor.com

Diane Meegan
212-330-8512
Investor Relations
dmeegan@daxor.com


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES